ZFIN Image: Hofsteen et al., 2018, Fig. 5

Image

Figure Caption

Fig. 5

ALPK2 Inhibits WNT/β-Catenin Signaling to Promote Cardiogenesis

(A) Transcripts abundance of ALPK2 in control and ALPK2 shRNA-transfected cardiac progenitor cells (CPCs) derived from human embryonic stem cells (hESCs).

(B) Flow cytometric plot and graphs quantifying venus expression driven by β-catenin activated reporter (BAR) in live CPCs following control or ALPK2 shRNA transfection as hESCs.

(C) Western blot protein expression analysis of WNT/β-catenin signaling modulators in wild-type and CRISPR/Cas9-mediated ALPK2 mutant hESC-derived CPCs (ALPK2Δ10) treated with a small molecule direct tankyrase inhibitor XAV939 (1 μM).

(D) Western blotting for the WNT/β-catenin signaling target LEF1 in wild-type and ALPK2Δ10 cells with or without the addition of XAV939 (0 or 1 μM).

(E) TNNT2 flow cytometry quantification of day 14 cardiomyocytes derived from wild-type and ALPK2Δ10 hESCs treated with XAV939 (0, 1, 5 μM).

(F) Representative images of heat shocked (hs) wild-type and hsWnt8b transgenic zebrafish carrying a transgene for the epicardium (tcf21:DsRed) at 96 hpf. Fish were counterstained with an activated leukocyte cell adhesion molecule (ALCAM; magenta).

N = 3–5 biological replicates, and data are displayed as mean ± SEM. * = p ≤ 0.05. See also Figure S4.

Figure Data

Phenotype details

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ iScience